Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

George Miguel

Psychiatry Joliet, IL Medical Doctor

NPI 1174591010 CMS profile 8076

210 N Hammes Ave Ste 108, Joliet, IL 60435

Open in the dashboard

General payments

$2,495

124 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, George Miguel of Joliet, IL is reported in the CMS Open Payments database as having received $2,495 across 124 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $217 2
2023 General $121 1
2022 General $191 10
2021 General $421 20
2020 General $791 46
2019 General $753 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Miguel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to George Miguel were reported at $217. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year George Miguel Psychiatry median Middle half National median
2019 $753 $184 $59–$605 $163
2020 $791 $119 $36–$372 $114
2021 $421 $143 $43–$576 $132
2022 $191 $153 $50–$590 $149
2023 $121 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $217 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $464 25 payments
  2. Sunovion Pharmaceuticals Inc. $331 19 payments
  3. Otsuka America Pharmaceutical, Inc. $329 17 payments
  4. Janssen Pharmaceuticals, Inc $225 13 payments
  5. Abiomed $217 2 payments
  6. Vanda Pharmaceuticals Inc. $190 13 payments
  7. AbbVie, Inc. $137 2 payments
  8. Lundbeck LLC $131 8 payments
  9. Alkermes, Inc. $97 6 payments
  10. Pfizer Inc. $91 1 payment
  11. Other $283 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,476 119 payments
  2. Education $18 5 payments
Products named General payments · program years 2019–2025
  1. LATUDA $331 19 payments
  2. TRINTELLIX $330 13 payments
  3. ABILIFY MAINTENA $238 15 payments
  4. INVEGA SUSTENNA $225 13 payments
  5. HETLIOZ $190 13 payments
  6. FANAPT $190 13 payments
  7. REXULTI $183 7 payments
  8. VRAYLAR $137 2 payments
  9. SPRAVATO $134 9 payments
  10. ARISTADA INITIO $97 6 payments
  11. Other $1,054 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

6,365

Median for Psychiatry & Neurology: 100

Drug cost

$244,367

Median for Psychiatry & Neurology: $2,986

Branded share of claims

9%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 30 $88,534
Chlorpromazine Hcl Generic 97 $21,541
Vraylar Cariprazine Hcl Brand 11 $16,297
Clomipramine Hcl Generic 47 $14,931
Clozapine Generic 174 $11,394
Divalproex Sodium Generic 253 $10,498
Aripiprazole Generic 187 $7,067
Divalproex Sodium Er Divalproex Sodium Brand 174 $6,612
Naltrexone Hcl Generic 163 $5,869
Fluvoxamine Maleate Generic 120 $4,745

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Records

124 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record